Latest papers

[Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].

Design, synthesis and biological evaluation of carbohydrate-functionalized cyclodextrins and liposomes for hepatocyte-specific targeting.

[A case with local recurrence of rectal cancer that responded to S-1 and PSK with long-term complete response].

Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats.

Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-κB inhibitors in Hodgkin's lymphoma.

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.

[Expression of interleukin-6 in rat model of doxorubicin-induced nephropathy].

[Management of hypertrophic scars and keloids].

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

Macrolides of the bafilomycin family produced by Streptomyces sp. CS.

The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles.

Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines.

[A case of primary malignant lymphoma of the prostate presenting as urinary retention].

7-O-descarbamoyl-7-hydroxygeldanamycin, a minor component from the gdmN disruption mutant of Streptomyces hygroscopicus 17997.

Core/shell nanoparticles for pH-sensitive delivery of doxorubicin.

Cardiac complications from cancer therapy.

Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).

Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.